CoChat

NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models

Open access
Ghatak, Swagata, Dolatabadi, Nima, Gao, Richard, Wu, Yin, Scott, Henry, Trudler, Dorit, Sultan, Abdullah, Ambasudhan, Rajesh, Nakamura, Tomohiro, Masliah, Eliezer, Talantova, Maria, Voytek, Bradley, Lipton, Stuart A. · 2021 · Molecular Psychiatry
Cited by 77

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Beginning at early stages, human Alzheimer’s disease (AD) brains manifest hyperexcitability, contributing to subsequent extensive synapse loss, which has been linked to cognitive dysfunction. No current therapy for AD is disease-modifying. Part of the problem with AD drug discovery is that transgenic mouse models have been poor predictors of potential human treatment. While it is undoubtedly important to test drugs in these animal models, additional evidence for drug efficacy in a human context might improve our chances of success. Accordingly, in order to test drugs in a human context, we have developed a platform of physiological assays using patch-clamp electrophysiology, calcium imaging, and multielectrode array (MEA) experiments on human (h)iPSC-derived 2D cortical neuronal cultures and 3D cerebral organoids. We compare hiPSCs bearing familial AD mutations vs. their wild-type (WT) isogenic controls in order to characterize the aberrant electrical activity in such a human context. Here, we show that these AD neuronal cultures and organoids manifest increased spontaneous action potentials, slow oscillatory events (~1 Hz), and hypersynchronous network activity. Importantly, the dual-allosteric NMDAR antagonist NitroSynapsin, but not the FDA-approved drug memantine, abrogated this hyperactivity. We propose a novel model of synaptic plasticity in which aberrant neural networks are rebalanced by NitroSynapsin. We propose that hiPSC models may be useful for screening drugs to treat hyperexcitability and related synaptic damage in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-020-0776-7

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 77

Metadata

Authors
Ghatak, S., Dolatabadi, N., Gao, R., Wu, Y., Scott, H., Trudler, D., Sultan, A., Ambasudhan, R., Nakamura, T., Masliah, E., Talantova, M., Voytek, B., & Lipton, S. A.
Venue
Molecular Psychiatry
Published
2020-05-29
Volume
26
Issue
10
Pages
5751-5765
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3029039883
Cited by
77
References
18
FWCI
5.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. https://app.cochat.ai/papers/10.1038/s41380-020-0776-7
The paper
Ghatak, S., Dolatabadi, N., Gao, R., Wu, Y., Scott, H., Trudler, D., Sultan, A., Ambasudhan, R., Nakamura, T., Masliah, E., Talantova, M., Voytek, B., & Lipton, S. A. (2021). NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. Molecular Psychiatry. https://doi.org/10.1038/s41380-020-0776-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.